These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28075539)

  • 1. Commentary on Nardone et al. (2016): Satisfaction, dissatisfaction and complicating the nicotine-reduction strategy with more nicotine.
    Kozlowski LT
    Addiction; 2016 Dec; 111(12):2217-2218. PubMed ID: 28075539
    [No Abstract]   [Full Text] [Related]  

  • 2. Rethinking therapeutic and recreational nicotine products: a commentary on Hatsukami et al.
    Borland R; Gartner C
    Tob Control; 2016 May; 25(3):245. PubMed ID: 27103635
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on Pateman et al. (2016): Optimizing the wait for the 'right time'.
    Duaso MJ; Walsh H
    Addiction; 2016 Jun; 111(6):1057-8. PubMed ID: 27157904
    [No Abstract]   [Full Text] [Related]  

  • 4. [Harm reduction strategy in tobacco control].
    Gorini G
    Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential impact of vaporized nicotine products on vulnerable subpopulations.
    Gartner C
    Addiction; 2017 Jan; 112(1):18-19. PubMed ID: 27154404
    [No Abstract]   [Full Text] [Related]  

  • 6. Australian urban Indigenous smokers' perspectives on nicotine products and tobacco harm reduction.
    Yuke K; Ford P; Foley W; Mutch A; Fitzgerald L; Gartner C
    Drug Alcohol Rev; 2018 Jan; 37(1):87-96. PubMed ID: 28493405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobacco harm reduction: the need for new products that can compete with cigarettes.
    Fagerström KO; Bridgman K
    Addict Behav; 2014 Mar; 39(3):507-11. PubMed ID: 24290207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The case for the WHO Advisory Note, Global Nicotine Reduction Strategy.
    Hatsukami DK; Zaatari G; Donny E
    Tob Control; 2017 Mar; 26(e1):e29-e30. PubMed ID: 27357938
    [No Abstract]   [Full Text] [Related]  

  • 9. Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.
    Bell S; Dean J; Gilks C; Boyd MA; Fitzgerald L; Mutch A; Baker P; Neilsen G; Gartner CE
    Int J Environ Res Public Health; 2017 Jul; 14(7):. PubMed ID: 28718828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tobacco, nicotine and harm reduction.
    Le Houezec J; McNeill A; Britton J
    Drug Alcohol Rev; 2011 Mar; 30(2):119-23. PubMed ID: 21375611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine regulation and tobacco harm reduction in the UK.
    Britton J; McNeill A
    Lancet; 2013 Jun; 381(9881):1879-80. PubMed ID: 23725716
    [No Abstract]   [Full Text] [Related]  

  • 12. Toward a comprehensive policy on nicotine delivery products and harm reduction.
    Solyst J
    Food Drug Law J; 2012; 67(4):393-404, i. PubMed ID: 24640613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for a nicotine-reduction strategy in the cigarette endgame: Alternative tobacco harm reduction scenarios.
    Kozlowski LT
    Int J Drug Policy; 2015 Jun; 26(6):543-7. PubMed ID: 25795345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction.
    Kozlowski LT; Abrams DB
    BMC Public Health; 2016 May; 16():432. PubMed ID: 27221096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory issues concerning the development and circulation of nicotine-containing products: a qualitative study.
    Rooke C; McNeill A; Arnott D
    Nicotine Tob Res; 2013 Jun; 15(6):1052-9. PubMed ID: 23128517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harm reduction policies for tobacco users.
    Gartner C; Hall W
    Int J Drug Policy; 2010 Mar; 21(2):129-30. PubMed ID: 19944582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harm reduction and the medicalisation of tobacco use.
    Rooke C
    Sociol Health Illn; 2013 Mar; 35(3):361-76. PubMed ID: 22670865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
    Kozlowski LT
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cigarette prohibition and the need for more prior testing of the WHO TobReg's global nicotine-reduction strategy.
    Kozlowski LT
    Tob Control; 2017 Mar; 26(e1):e31-e34. PubMed ID: 27357937
    [No Abstract]   [Full Text] [Related]  

  • 20. Making smokers different with nicotine: NRT and quitting.
    Keane H
    Int J Drug Policy; 2013 May; 24(3):189-95. PubMed ID: 23465645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.